GSTM1 and Cognitive impairment: Indeed, initial studies of factors, such as selected cytokines, stress hormones, CSF proteins, lipids, or Hb levels, have provided interesting information about changes in biomarkers that evolve during the course of the treatment of cancer patients, and also about genetic polymorphisms predisposing to cognitive deficits.